Skip NavigationMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting Club
PRO
LivestreamMenu
- Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since Medicare coverage of obesity drugs launched in July.
- In an exclusive interview, Ricks said 70% of those patients are on Lilly medicines.
- They are the latest metrics on how much the coverage is expanding access to the medicines, and who appears to be gaining more momentum among new patients between Lilly and its chief rival, Novo.
watch nowVIDEO05:32Eli Lilly CEO Dave Ricks: One-third of new GLP-1 pill patients are taking FoundayoHalftime Report
Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since Medicare coverage of obesity drugs launched in July, and 70% of those patients are on Lilly medicines.
In an exclusive interview with CNBC, Ricks called the rollout of coverage “very encouraging” so far saying its expansion of the broader GLP-1 market “is what we had hoped.” His comments offer the latest metrics on how much the coverage is expanding access to the medicines, and who appears to be gaining more momentum among new patients between Lilly and its chief rival, Novo.
Lilly’s blockbuster obesity injection Zepbound appears to be the biggest winner of Medicare coverage so far.
“We’re capturing about seven out of 10 of those new patients, and a lot are still on Zepbound,” he said. “I think we still see physicians focusing on those with the most body weight and the most complications. That’s where Zepbound plays a big role.”
Lilly’s newly launched obesity pill Foundayo plays a larger role for patients who are looking for a convenient treatment option and “maybe just need to lose 25 to 30 pounds,” Ricks added.
He said he hasn’t heard of many logistical issues with the rollout, saying the Centers for Medicare and Medicaid Services “did a nice job rolling this out,” educating physicians and working with both companies and the insurance system.
